Our findings suggest that lnc-HIBADH-4 may serve as a potential biomarker for ALS, and maintaining its expression and CTSD activity may represent a promising pharmacological protective intervention against neurodegeneration in ALS. Here, CTSD is linked to amyotrophic lateral sclerosis.